Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Novogen — Shareholder Meeting (April 2013)
46 slides from Kazia Therapeutics's shareholder meeting presentation, Apr 19, 2013
Slide 1: Novogen
@, @8@ Novocen -e Sao NOVOGEN
Slide 2: General Meeting of Shareholders
NOVOGEN General Meeting of Shareholders 19 April
Slide 3: Resolution 1. Approval to raise capital
General Meeting 19 April 2013 NOVOGEN Resolution 1. Approval to raise capital Recurrent costs $1.4M (approx.) Salaries/directors’ fees 40% Legal/accounting/audit 60% Patents Office ASX/NASDAQ R & D costs Pre-clinical program + Phase 1a $1.2M Analog program $0.5M Other $1.0M
Slide 4: Resolution 1. Approval to raise capital
General Meeting 19 April 2013 NOVOGEN Resolution 1. Approval to raise capital Approval under Listing Rule 7.3 Maximum $10M Maximum 1:2 options Maximum discount of 20% of 5-day VWAP Within 3 months of GM
Slide 5: Resolution voting results
General Meeting 19 April 2013 NOVOGEN Resolution 1 Vote type Voted % FOR 23,783,292 97.16 AGAINST 218,718 1.47 OPEN - USABLE 208,563 1.40 OPEN - CONDITIONAL 2,000 0.01 OPEN - UNUSABLE 178,990 N/A ABSTAIN 6,500 N/A EXCLUDED 0 N/A 5
Slide 6: Resolution: Issue of shares
General Meeting 19 April 2013 NOVOGEN Resolution 2 Issue of shares Allotment of shares: •250,000 B. Palmer •1,429,782 Glycotex Inc •15,279,782 Triaxial acquisition
Slide 7: Resolution voting results
General Meeting 19 April 2013 NOVOGEN Resolution 2 Vote type Voted % FOR 13,265,319 93.33 AGAINST 737,348 5.19 OPEN - USABLE 208,563 1.47 OPEN - CONDITIONAL 2,000 0.01 OPEN - UNUSABLE 215,740 N/A ABSTAIN 606,800 N/A EXCLUDED 9,363,293 N/A
Slide 8: Resolution: Issue of shares to Phytose Corp. Pty Ltd
General Meeting 19 April 2013 NOVOGEN Resolution 3 Issue of shares to Phytose Corp. Pty Ltd 1,800,000 shares as part consideration of First Tranche of shares per acquisition of Triaxial Pharmaceuticals Pty Ltd
Slide 9: Resolution voting results
General Meeting 19 April 2013 NOVOGEN Resolution 3 Vote type Voted % FOR 22,659,788 95.99 AGAINST 736,348 3.12 OPEN – USABLE 208,563 0.88 OPEN – CONDITIONAL 2,000 0.01 OPEN – UNUSABLE 178,990 N/A ABSTAIN 612,800 N/A EXCLUDED 3,864,137 N/A
Slide 10: Resolution: Issue of shares for Convertible Notes
General Meeting 19 April 2013 NOVOGEN Resolution 4 Issue of shares for Convertible Notes • Acquisition of Triaxial Pharmaceuticals Pty Ltd for $1.88M • Purchase funded by Convertible Notes from 6 shareholders • All shareholders have elected to receive shares • $1.5M of Notes remaining: (a) Completio
Slide 11: Resolution voting results
General Meeting 19 April 2013 NOVOGEN Resolution 4 Vote type Voted % FOR 22,659,788 93.73 AGAINST 659,848 4.65 OPEN – USABLE 228,563 1.61 OPEN – CONDITIONAL 2,000 0.01 OPEN – UNUSABLE 215,740 N/A ABSTAIN 618,374 N/A EXCLUDED 9,362,293 N/A
Slide 12: Novogen
@, ege NOVOGEN eo @,08 NOVOGEN
Slide 13: Our Mission
NOVOGEN Our Mission To bring the ability to conquer cancer into the reach of the common man
Slide 14: Comprehensive Cancer Therapy
NOVOGEN Comprehensive Cancer Therapy Therapy targeting both regular cancer cells and their progenitor cells - cancer stem cells
Slide 15: Conventional cancer therapy
Conventional cancer therapy NOVOGEN Remission Recurrence
Slide 16: Comprehensive Cancer Therapy
Comprehensive Cancer Therapy NOVOGEN Short term Remission Long-term Remission
Slide 17: A new company
NOVOGEN NOVOGEN A new company with: a new technology platform for cancer drug development a new management team a new Board
Slide 18: Disclaimer
Disclaimer NOVOGEN This presentation is confidential and is not an offer or a recommendation or intended to influence you in any way in making an investment decision or take any other action. In particular, Novogen: a.does not warrant the accuracy or completeness of the information including any for
Slide 19: Company history
Company history NOVOGEN 1994 Norvet Ltd formed and listed (ASX). (‘NRT’). Veterinary and consumer health products. 1997 Veterinary business sold. Focus on isoflavone drugs and OTC business. Name change to Novogen. 1998 Lists on NASDAQ (‘NVGN’). 1998 - 2008 Active drug R&D programs. Broad drug techno
Slide 20: Triaxial history
Triaxial history Triaxial Pharmaceuticals Pty Ltd formed by 3 ex-Novogen scientists: Andrew Heaton, David Brown and Graham Kelly. TRIAXIAL GK - Founder of Novogen, variously CEO and Chairman. Responsible for discovery of isoflavonoid (benzopyran) drug opportunity. Resigned in 2007. AH - Senior Chemi
Slide 21: Gen technology platform
Gen 1 technology platform NOVOGEN Simple benzopyran molecules Unique anti-cancer action pan cancer effect tumour-specific unaffected by multi-drug resistance mechanisms restore chemo-sensitivity modest anti-cancer stem cell activity 4 lead drug candidates Tested in > 800 patients Evidence of efficac
Slide 22: Gen technology platform
Gen 2 technology platform NOVOGEN Need to: increase bio-availability increase potency against both cancer cells and cancer stem cells improve manufacturing efficiencies. Challenge: new technology required to create a new family of more complex benzopyrans need to overcome design and manufacturing li
Slide 23: Gen technology platform
Gen 2 technology platform NOVOGEN Manufacturing and design breakthrough larger, more complex molecules SUPER-BENZOPYRANS Change in electrical field charges increased bio-availability Substantial increase in potency both cancer stem cells and regular cancer cells COMPREHENSIVE ANTI-CANCER THERAPY
Slide 24: Standard cancer cell killing
Standard cancer cell killing NOVOGEN Ability of first library of super-benzopyran drugs to kill standard cancer cells of different cancer types. CS-5 and -6 highly active; CS-2 and -3 less active and typical of earlier Novogen benozopyran drugs; CS-13-20 unacceptably low activity. CS20 CS19 CS18 CS1
Slide 25: Active against cancer stem cells
Active against cancer stem cells NOVOGEN CS-6 is highly active against ovarian cancer stem cell line. Note that the anti-cancer effect starts at 4 hours and occurs t very low dose rates (2 nanomolar), indicating a highly efficient anti-cancer effect. Mazor EPL CS6-R127 - NT Mean vs Time (3-pt Smooth
Slide 26: Bending: Birth of Super-Benzopyrans
Bending: Birth of Super-Benzopyrans NOVOGEN Initial synthesis of benzopyrans had a simplistic approach designed to manufacture one or two compounds, not families of compounds. RO O O RO O
Slide 27: The Gen II Technology
The Gen II Technology NOVOGEN Gen I: Slow linear formation of molecules.…very limited “dynamic range” Gen II: Rapid generation of molecules with tremendous variety and “dynamic range”
Slide 28: The Bend Technology
The Bend Technology $ NOVOGEN "Z SS a eS
Slide 29: Gen II Technology
Gen II Technology NOVOGEN Far more efficient- now use 4 manufacturing steps not 8+ Each manufacturing step can add a far wider range of groups giving greater molecular diversity, thereby maximizing the possibility of getting a hit Range of groups added is focused we do not have a shotgun approach. E
Slide 30: Manufacture of Clean Pharmaceutical Grade Products
Manufacture of Clean Pharmaceutical Grade Products NOVOGEN Implementation of 4 step manufacturing process investigated scope of different groups that could be added in a controlled fashion and purity. Analysis of material demonstrated the ability to manufacture pure compounds for screening. DAD1 A,
Slide 31: Design Compounds with Potent Anti-cancer Activity
Design Compounds with Potent Anti-cancer Activity NOVOGEN Construction of library of learning set of molecules to develop new exciting molecules that could not previously be manufactured by older technology. Breast MDA-MB-231 MCF7 Prostate LNCap PC3 DU145 Colon SW480 HT-29 HCT-15 HCT116 Glioma T98G
Slide 32: Stealth technology assay
Stealth technology assay NOVOGEN CS20 CS19 CS18 CS17 CS16 CS15 CS14 CS13 CS6 CS5 CS3 CS2 Colon SW480 Colon HT-29 Colon HCT-15 Colon HCT116 0 20 40 60 80 100
Slide 33: 'Stealth' technology and the cancer cell wall defenses
‘Stealth’ technology and the cancer cell wall defenses NOVOGEN Drug Target Cell Wall
Slide 34: Stealth Technology-older drugs blocked at cell wall
Stealth Technology-older drugs blocked at cell wall NOVOGEN Drug Cell Wall Target
Slide 35: Stealth Technology-avoids defense mechanism
Stealth Technology-avoids defense mechanism NOVOGEN Cell Wall Target Drug+ ST
Slide 36: Bolt on Stealth Technology
Bolt on Stealth Technology NOVOGEN CS20 CS18 CS6 Breast MDA-MB-231 Breast MCF7 Prostate LNCaP Prostate PC3 Prostate DU145 Colon SW480 Colon HT-29 Colon HCT-15 Colon HCT116 Glioma T98G Glioma U87-MG Glioma A172 Lung H460 Lung A549 Skin A-431 Melanoma A375 Melanoma G-361
Slide 37: Enantiomers
Enantiomers NOVOGEN CS-6 can exist in left hand and right hand form. Initial analysis was completed on a mixture of the two. We have developed methodologies to produce pure left and right hand forms of CS-6.
Slide 38: CS-6 Enantiomer Analysis
CS-6 Enantiomer Analysis NOVOGEN 0.2 0.18 0.16 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 DADY U87-MG SNB-19 EPL-CS6(1+2) EPL-CS6(1) EPL-CS6(2)
Slide 39: CS-6: Path to clinic
CS-6: Path to clinic NOVOGEN Critical pre-clinical path being undertaken by one organisation (experienced CRO) Manufacturing facility meets requirements for ALL regulatory jurisdictions (USA, EU, Aust/NZ…) Manufacture of the CS-6 enantiomer and its finished sterile formulation being completed at Swi
Slide 40: Work In-Progress
Work In-Progress NOVOGEN Analog Programs Program 1: CS-6 based analogs ensuring robust patent strategy to protect CS-6 and its method of manufacture. New analogs comprising CS-6 “brothers and sisters” that help protect our IP position and also test “Double stealth Technology”. The rapid generation o
Slide 41: Novogen
® ego NOVOCEN eo Sam NOVOGEN
Slide 42: CS-6: Path to Clinic
CS-6: Path to Clinic Prepare intravenous formulation Mouse PK study ADME Phase la study 28-day chronic toxicity NOVOGEN MTD and preliminary toxicity Mouse Xenograft
Slide 43: CS-6: Path to Clinic
CS-6: Path to Clinic Research collaborations + contract research. To determine most appropriate clinical indication. Scientific Advisory Panel Main study Glioblastoma (subcutaneous) xenograft Glioblastoma (orthotopic) xenograft Temozolomide-resistant glioblastoma multiforme NOVOGEN Yale/Mazor Ovaria
Slide 44: CS-6 Ovarian Cancer Stem Cells
CS-6 Ovarian Cancer Stem Cells NOVOGEN NT 0.1 µg/ml 10 µg/ml Tara-R182 cells 24 hours NT 0.1 µg/ml 10 µg/ml
Slide 45: Cancer therapy snapshots
Cancer therapy snapshots NOVOGEN Drug Indication Benefit Market Size Herceptin trastuzumab Herceptin HER2+ breast cancer 20-25% all cases; Phase 4 only) ($50,000 p.a. treatment cost) Increase from 20.3 vs 25.1 months survival $6.4b pa gleevec Gleevec Chronic myeloid leukaemia ($$50,000 p.a. treatmen
Slide 46: Website
Website http://www.novogen.com NOVOGEN